{"name":"RemeGen Co., Ltd.","slug":"remegen-co-ltd","ticker":"","exchange":"","domain":"remegen.com","description":"RemeGen Co., Ltd. is a biotechnology company focused on the research and development of innovative therapies, particularly in oncology. The company has a robust pipeline of 66 drugs, with several in early clinical phases, positioning it as a promising player in the biotech sector.","hq":"Yantai","founded":0,"employees":"N/A","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":16,"colorKey":"immunology","drugs":[{"name":"Telitacicept Freeze-dried powder Injection 80mg","genericName":"Telitacicept Freeze-dried powder Injection 80mg","slug":"telitacicept-freeze-dried-powder-injection-80mg","indication":"Other","status":"marketed"},{"name":"Furmonertinib Mesilate Tablets Monotherapy","genericName":"Furmonertinib Mesilate Tablets Monotherapy","slug":"furmonertinib-mesilate-tablets-monotherapy","indication":"Other","status":"phase_2"},{"name":"Placebo plus standard therapy","genericName":"Placebo plus standard therapy","slug":"placebo-plus-standard-therapy","indication":"Other","status":"marketed"},{"name":"RC108","genericName":"RC108","slug":"rc108","indication":"Other","status":"phase_2"},{"name":"RC118","genericName":"RC118","slug":"rc118","indication":"Other","status":"phase_1"},{"name":"RC148","genericName":"RC148","slug":"rc148","indication":"Other","status":"phase_2"},{"name":"RC148 Monotherapy","genericName":"RC148 Monotherapy","slug":"rc148-monotherapy","indication":"Other","status":"phase_1"},{"name":"RC278","genericName":"RC278","slug":"rc278","indication":"Other","status":"phase_1"},{"name":"RC48-ADC in Combination with gemcitabine","genericName":"RC48-ADC in Combination with gemcitabine","slug":"rc48-adc-in-combination-with-gemcitabine","indication":"Other","status":"phase_2"},{"name":"RC88","genericName":"RC88","slug":"rc88","indication":"Other","status":"phase_2"},{"name":"RC98","genericName":"RC98","slug":"rc98","indication":"Other","status":"phase_1"},{"name":"Sequential CTX","genericName":"Sequential CTX","slug":"sequential-ctx","indication":"Other","status":"phase_2"},{"name":"Sequential Epirubicin","genericName":"Sequential Epirubicin","slug":"sequential-epirubicin","indication":"Other","status":"phase_2"},{"name":"Toripalimab （12weeks）","genericName":"Toripalimab （12weeks）","slug":"toripalimab-12weeks","indication":"Other","status":"phase_2"},{"name":"Toripalimab （18weeks）","genericName":"Toripalimab （18weeks）","slug":"toripalimab-18weeks","indication":"Other","status":"phase_2"},{"name":"intravitreal injection of RC28-E","genericName":"intravitreal injection of RC28-E","slug":"intravitreal-injection-of-rc28-e","indication":"Other","status":"phase_2"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":11,"colorKey":"oncology","drugs":[{"name":"Disitamab Vedotin for injection","genericName":"Disitamab Vedotin for injection","slug":"disitamab-vedotin-for-injection","indication":"Locally advanced or metastatic non-small cell lung cancer","status":"phase_2"},{"name":"Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine","genericName":"Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine","slug":"disitamab-vedotin-tislelizumab-oxaliplatin-capecitabine","indication":"HER2-positive gastric or gastroesophageal junction cancer (phase 3)","status":"phase_3"},{"name":"Pertuzumab Injection","genericName":"Pertuzumab Injection","slug":"pertuzumab-injection","indication":"HER2-positive metastatic breast cancer (in combination with trastuzumab and chemotherapy)","status":"phase_3"},{"name":"RC-28E","genericName":"RC-28E","slug":"rc-28e","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"RC148 plus Carboplatin and Paclitaxel","genericName":"RC148 plus Carboplatin and Paclitaxel","slug":"rc148-plus-carboplatin-and-paclitaxel","indication":"Advanced or metastatic solid tumors (in combination with carboplatin and paclitaxel)","status":"phase_3"},{"name":"Tislelizumab plus Carboplatin and Paclitaxel","genericName":"Tislelizumab plus Carboplatin and Paclitaxel","slug":"tislelizumab-plus-carboplatin-and-paclitaxel","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"Albumin-bound Paclitaxone","genericName":"Albumin-bound Paclitaxone","slug":"albumin-bound-paclitaxone","indication":"Non-small cell lung cancer","status":"phase_2"},{"name":"Disitamab Vedotin Injection","genericName":"Disitamab Vedotin Injection","slug":"disitamab-vedotin-injection","indication":"Locally advanced or metastatic gastric adenocarcinoma","status":"phase_2"},{"name":"Disitamab Vedotin Injection （18 weeks）","genericName":"Disitamab Vedotin Injection （18 weeks）","slug":"disitamab-vedotin-injection-18-weeks","indication":"Relapsed or refractory diffuse large B-cell lymphoma","status":"phase_2"},{"name":"RC28-E","genericName":"RC28-E","slug":"rc28-e","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"RC48-ADC","genericName":"RC48-ADC","slug":"rc48-adc","indication":"HER2-positive gastric cancer","status":"phase_3"}]}],"pipeline":[{"name":"Disitamab Vedotin for injection","genericName":"Disitamab Vedotin for injection","slug":"disitamab-vedotin-for-injection","phase":"phase_2","mechanism":"Disitamab vedotin is a monoclonal antibody-drug conjugate that targets the epidermal growth factor receptor (EGFR) and delivers a microtubule inhibitor to cancer cells.","indications":["Locally advanced or metastatic non-small cell lung cancer"],"catalyst":""},{"name":"Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine","genericName":"Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine","slug":"disitamab-vedotin-tislelizumab-oxaliplatin-capecitabine","phase":"phase_3","mechanism":"This combination therapy targets HER2-positive gastric cancer through antibody-drug conjugate-mediated tumor cell killing, immune checkpoint inhibition, and chemotherapy-induced DNA damage.","indications":["HER2-positive gastric or gastroesophageal junction cancer (phase 3)"],"catalyst":""},{"name":"Pertuzumab Injection","genericName":"Pertuzumab Injection","slug":"pertuzumab-injection","phase":"phase_3","mechanism":"Pertuzumab is a monoclonal antibody that binds to HER2 and blocks its dimerization with other HER receptors, preventing cancer cell growth signaling.","indications":["HER2-positive metastatic breast cancer (in combination with trastuzumab and chemotherapy)","HER2-positive early-stage breast cancer (neoadjuvant and adjuvant settings)"],"catalyst":""},{"name":"RC-28E","genericName":"RC-28E","slug":"rc-28e","phase":"phase_3","mechanism":"RC-28E is a monoclonal antibody targeting PD-1.","indications":["Non-small cell lung cancer, PD-L1 positive"],"catalyst":""},{"name":"RC148 plus Carboplatin and Paclitaxel","genericName":"RC148 plus Carboplatin and Paclitaxel","slug":"rc148-plus-carboplatin-and-paclitaxel","phase":"phase_3","mechanism":"RC148 is a PD-L1 inhibitor combined with standard chemotherapy (carboplatin and paclitaxel) to enhance anti-tumor immune response while providing cytotoxic chemotherapy.","indications":["Advanced or metastatic solid tumors (in combination with carboplatin and paclitaxel)"],"catalyst":""},{"name":"Telitacicept Freeze-dried powder Injection 80mg","genericName":"Telitacicept Freeze-dried powder Injection 80mg","slug":"telitacicept-freeze-dried-powder-injection-80mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tislelizumab plus Carboplatin and Paclitaxel","genericName":"Tislelizumab plus Carboplatin and Paclitaxel","slug":"tislelizumab-plus-carboplatin-and-paclitaxel","phase":"phase_3","mechanism":"Tislelizumab is a monoclonal antibody that targets PD-1, while carboplatin and paclitaxel are chemotherapeutic agents that interfere with DNA replication and cell division.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"Albumin-bound Paclitaxone","genericName":"Albumin-bound Paclitaxone","slug":"albumin-bound-paclitaxone","phase":"phase_2","mechanism":"Albumin binding enhances the solubility of paclitaxel, allowing for higher doses to be administered.","indications":["Non-small cell lung cancer","Breast cancer","Ovarian cancer"],"catalyst":""},{"name":"Disitamab Vedotin Injection","genericName":"Disitamab Vedotin Injection","slug":"disitamab-vedotin-injection","phase":"phase_2","mechanism":"Disitamab vedotin is a monoclonal antibody-drug conjugate that targets the Trop-2 receptor.","indications":["Locally advanced or metastatic gastric adenocarcinoma","Locally advanced or metastatic esophageal squamous cell carcinoma"],"catalyst":""},{"name":"Disitamab Vedotin Injection （18 weeks）","genericName":"Disitamab Vedotin Injection （18 weeks）","slug":"disitamab-vedotin-injection-18-weeks","phase":"phase_2","mechanism":"Anti-CD6 monoclonal antibody","indications":["Relapsed or refractory diffuse large B-cell lymphoma"],"catalyst":""},{"name":"Furmonertinib Mesilate Tablets Monotherapy","genericName":"Furmonertinib Mesilate Tablets Monotherapy","slug":"furmonertinib-mesilate-tablets-monotherapy","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo plus standard therapy","genericName":"Placebo plus standard therapy","slug":"placebo-plus-standard-therapy","phase":"marketed","mechanism":"Placebo plus standard therapy provides no active pharmacological intervention beyond the standard treatment already being administered.","indications":[],"catalyst":""},{"name":"RC108","genericName":"RC108","slug":"rc108","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"RC118","genericName":"RC118","slug":"rc118","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"RC148","genericName":"RC148","slug":"rc148","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"RC148 Monotherapy","genericName":"RC148 Monotherapy","slug":"rc148-monotherapy","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"RC278","genericName":"RC278","slug":"rc278","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"RC28-E","genericName":"RC28-E","slug":"rc28-e","phase":"phase_3","mechanism":"RC28-E is a monoclonal antibody targeting PD-1.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"RC48-ADC","genericName":"RC48-ADC","slug":"rc48-adc","phase":"phase_3","mechanism":"RC48-ADC is an antibody-drug conjugate that targets HER2-positive cancer cells by delivering cytotoxic payload directly to tumor cells expressing the HER2 receptor.","indications":["HER2-positive gastric cancer","HER2-positive breast cancer","HER2-positive biliary tract cancer"],"catalyst":""},{"name":"RC48-ADC in Combination with gemcitabine","genericName":"RC48-ADC in Combination with gemcitabine","slug":"rc48-adc-in-combination-with-gemcitabine","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"RC88","genericName":"RC88","slug":"rc88","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"RC98","genericName":"RC98","slug":"rc98","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Sequential CTX","genericName":"Sequential CTX","slug":"sequential-ctx","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Sequential Epirubicin","genericName":"Sequential Epirubicin","slug":"sequential-epirubicin","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Toripalimab （12weeks）","genericName":"Toripalimab （12weeks）","slug":"toripalimab-12weeks","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Toripalimab （18weeks）","genericName":"Toripalimab （18weeks）","slug":"toripalimab-18weeks","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"intravitreal injection of RC28-E","genericName":"intravitreal injection of RC28-E","slug":"intravitreal-injection-of-rc28-e","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNYkxRSnFLRXc5LWI2bzNEWGlWS29sWmd4ZE1iQ1h3RWxSS3huY2tXWTJXV09sdnFmOTZtQzdIT09nbDhSRmtkNjB2Y0gyN1BYSVhSa25seG5mcTdnRlQ0QTJlWTBIcWI1WFBpWVZTdWhJYnU4THF1cGtjdHBGQ2tub3R6ZzY0UGZXeEFKRnlTSHdta1ktOTB6d1JKUFF6MHFtSVVOY25CbEt6T1gtM0k2clZKSjI5UXdEUTJEWXZzQQ?oc=5","date":"2026-01-14","type":"deal","source":"European Pharmaceutical Review","summary":"AbbVie licenses novel bispecific antibody from RemeGen for $5bn - European Pharmaceutical Review","headline":"AbbVie licenses novel bispecific antibody from RemeGen for $5bn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOWkYwTWlfdWxsSC1UWDlfT0NNajZRRkM2XzFkUXdSa3Z1QXdvaHBEMFRvYS1oU0x4b2hkS013Wk10Zk4taEZYdmwxVDBvbk1Vem1hd2VXeWEwNndJMFRfdzB2b3hUYllHM1FmTXpib1I1aDAyYVhHRGJoOVZvMW1YeE50UGtZVVVWekpQbVh1ejl6bGdRVkt2LVVma1BFeTBjSlhXVEFn?oc=5","date":"2026-01-13","type":"deal","source":"BioWorld News","summary":"Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal - BioWorld News","headline":"Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNdURZNjNCalhrWXVla1lnQi1ENzlMeUlZY29qRjltYTZlMUw1NUdiMnhuWXNXMHlzd181cDQxTWtQUWJDNnZfQzRjWVBEbXFJTlA3SzR1RHdVdnhNUGRTMjlLdk9rV2M4SmpmNUdSOVQzSEdUdUYzOUlPdnV5SFhNTGlTVFROdXZPZHY1a282R1RralJvTTMwSWFLRjhBUUdQTF8tV0tyX2d5ZU8wTGpRNGZUM1ZuSGJF?oc=5","date":"2026-01-13","type":"deal","source":"Contract Pharma","summary":"AbbVie, RemeGen Partner on Novel Bispecific Antibody for Advanced Tumors - Contract Pharma","headline":"AbbVie, RemeGen Partner on Novel Bispecific Antibody for Advanced Tumors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOYXhMeWNXRFJoeVJyeXVreUV5V2lCZ2toRGdpVUJaQTQ0TE1SZTdVQzRFRThpZ1VNSkRDOE5sRFpHS1V4MzJxbzBLdHdjMGE5T3hpRUtFRjRMejdyNVpuZnFLYXRwNmQ0dmI3RXg1UHJDb1YtZlRVUG84VkRPcmNGRDRkTDk3NlZfSTZwaUI4RW1aSmhZcVNlekRDTFk5NHc?oc=5","date":"2026-01-12","type":"deal","source":"Pharmaceutical Technology","summary":"JPM26: AbbVie and RemeGen kick off deals with $5.6bn oncology agreement - Pharmaceutical Technology","headline":"JPM26: AbbVie and RemeGen kick off deals with $5.6bn oncology agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNSjJjZlJxdWI0a3ZFQ1hTS2N4cW1GdDN5aUpCYVJaMFV3bTBtWDZsZUNEQm96WmR5eUFoc2hYRkhoaDd3SlpvQmZTckpTc0xsbFNDQzNVRFlfeHlHeS0xZWF4YklRbVVxeXB1ektCdGhXT0FGRjdSenBMMnRWTTBFUzYxZ2NFM3ZzZ0t6Y1JOQzd3alR4ZkhfSzRsYkdfZnRRTFlubHFtNDVEN2Jzc2tqWFo2VllEYlZHZy1wdHpZaG9sbFQ5SkpZQg?oc=5","date":"2026-01-12","type":"deal","source":"Reuters","summary":"AbbVie partners with China's RemeGen on experimental tumor treatment - Reuters","headline":"AbbVie partners with China's RemeGen on experimental tumor treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQLWx4b0NwUDFpbTR0TXBRaktBbXF6UWJQMEt3WXAzcXBNQmtmRUhFQlNNakt0QlNCaWU0YVVjVW43Mnp3VGV6XzBUUk1sWDFncW9VanZWSFM4Y0RGWU02WElQRGFTeDI4VFo5aGRjMWk4RnJuajlwWWZnczJDcWZnMV9hRDR4TVI3V0lvbTRPU2FZYkE3bmU4VmpVNmUxQUk?oc=5","date":"2026-01-12","type":"pipeline","source":"Fierce Biotech","summary":"AbbVie pens $5.6B pact with RemeGen to join PD-1xVEGF bispecific battle - Fierce Biotech","headline":"AbbVie pens $5.6B pact with RemeGen to join PD-1xVEGF bispecific battle","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxQUU9YcnV0U0tmbGZJNlpiYnZmSGZwUkY1U0o1SEZUc3FtTjlxQjEzYnBBVXg2ODNfQkNCdDQxU2E1Q0FMUHd6OTNlQkI3alpmMERlX3M1ZTZTZHhPVEVHY0hwVXBpLVpWU1hhRkw4M2JyWDZKNWlEaVA5WVAyZkRJbC1iZFE?oc=5","date":"2026-01-12","type":"pipeline","source":"pharmaphorum","summary":"JPM: AbbVie pays $650m upfront for RemeGen cancer drug - pharmaphorum","headline":"JPM: AbbVie pays $650m upfront for RemeGen cancer drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgJBVV95cUxNd1gxZ0tUU0dxMkN2bjRNQVptQXBJODBXTEpsRklRMFc5TkVCN0lOUGM3SUh3eEFTakUwZGRJbW1vM2V2aEFoMGFXZFc1b181MWJoY054ckx3WGR6RzhnakhPTkVxeUF1bkZfXzd3YW53NFI5T0xyS2xlcFBvT1FJNXN4UVY4NXVLU1dnRHdGVFNocnVYaW92RkQtVmZjZWxra20yLXl3MFFFZnpWbG5LeDI0TWxNSWQyUjZUTUxqN0FOSER2bF9tQl81b19McE5nSGQ4VzRvc0pNbmttekxGVThZVjhSaEEwMHkyeHliRVZhU19IYXF1clFRdFZja2VfS0FwbHNqUWoycUU4YXBsZjVONmxhRlhhVVE?oc=5","date":"2025-08-18","type":"pipeline","source":"PR Newswire","summary":"RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries - PR Newswire","headline":"RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and A","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxQOFJiRmc5Y3V0c3lXT0UxdnEtTFRVeU51c19HbVM4RjAxQmpYdVZvSDA5Ml9KdUZLb1BzX1FFd3EtNW5DSDJkbUVyc1dWVFJJcldjbXo2enRwOTViTlVTNEtBVFI3cEhxbXJMUnpwZFdZSEdZOWt4YlhwMWJEN3VDSnBB?oc=5","date":"2025-08-13","type":"trial","source":"pharmaphorum","summary":"More good news in Sjogren's as RemeGen trial delivers - pharmaphorum","headline":"More good news in Sjogren's as RemeGen trial delivers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPV25pYzVzX0thUm5nVm1fU1M4Sk1mNnhKblVhano1dl9aRkg2SnpoZEJERy1yZ2swVEw3NE5Bb2F2bDh2ME5MX3RrVGpFYmc3WXhpVW9BWmNyTVg4TDJEMWx5bGZydUJ6MlhFQlZUMjI2RVJYa0REc1EtbUE2QkJKeFBlR3REVU1HZ1RWYkx4Nm1wbHgy?oc=5","date":"2025-08-13","type":"trial","source":"BioPharma Dive","summary":"Vor says drug licensed from RemeGen succeeded in Sjögren’s study - BioPharma Dive","headline":"Vor says drug licensed from RemeGen succeeded in Sjögren’s study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAJBVV95cUxORGJHUDc3ZzE2dU1ZLUhXaFE5cFp4NUlZMjdGR2s4b2dMSlR4RjRSMjRGdEUxemFOVUYyTWo4NldiU19NNWVHaDVteks4UWthNWlud3c3aUpzaUxfMGZuRTB4eUtzSEYtUXpCdFQ1OWVkd3ZBYWZTY0ZjM1B1Y19kOGNCbjZObXpkMEhFcUxsRjBhbEpGS1dsYlNZQmdzUGVWR001MW1CbHoyX3RpaFc4N3JTTzdoS2JsbjMtd1V2OUxkUUE2a00xc2F6S2lFRlFRbl9GTWN0bTZJNnBoc2gtcWFUcTdnNVFhV3VWNEprMXBZR1U4cFZpaS1MRlZLM2tT?oc=5","date":"2025-06-25","type":"deal","source":"GlobeNewswire","summary":"Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset - GlobeNewswire","headline":"Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQRlRvazI2U1JFaHB6ZDUySW43d1BpZ0M2S0ljdmYzWVgwMjAwbHFZNXduWWJkNmVuWHF3cVZQYkotZ0dldEFkOU1kNTVmZ19TT0R5ZjVHMjV4dUNzSWM5VXcxQkFuLTVDZWtocHUtSHpYeW9KcW56SHR1S1dnOExpR09vLTk3aVBXLXAwWW5HZDRBTi1BalhCZE1NQngtV0d3cmJEQnFZbURJdVlQXzN4T294cG00V3dmdnVNaUlfSQ?oc=5","date":"2025-05-12","type":"deal","source":"Fierce Pharma","summary":"Pfizer partner RemeGen says HER2 ADC prolongs life in newly diagnosed bladder cancer - Fierce Pharma","headline":"Pfizer partner RemeGen says HER2 ADC prolongs life in newly diagnosed bladder cancer","sentiment":"neutral"}],"patents":[],"drugCount":27,"phaseCounts":{"phase_2":14,"phase_3":7,"marketed":2,"phase_1":4},"enrichmentLevel":2,"visitCount":7,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}